Table 2.
Associations between genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 and breast cancer and prostate cancer
| Outcome | Case, No | OR (95% CI) | P valuea |
|---|---|---|---|
| HMG-CoA reductase | |||
| Breast cancer | 122,977 | 0.84 (0.74–0.95) | 0.005 |
| Prostate cancer | 79,148 | 0.85 (0.73–1.00) | 0.05 |
| NPC1L1 | |||
| Breast cancer | 122,977 | 0.72 (0.58–0.90) | 0.005 |
| Prostate cancer | 79,148 | 1.23 (0.92–1.63) | 0.16 |
| PCSK9 | |||
| Breast cancer | 122,977 | 0.92 (0.86–0.98) | 0.01 |
| Prostate cancer | 79,148 | 0.81 (0.73–0.90) | 4.52e−05 |
HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A; NPC1L1, Niemann-Pick C1-Like 1; PCSK9, proprotein convertase subtilisin/kexin type 9; OR, Odds Ratio; CI, confidence interval
aSignificance threshold was set at P < 0.008 (Bonferroni-correction significance threshold calculated as 0.05 divided by 6 [3 drug targets against 2 outcomes])